about
The REG1 anticoagulation system: a novel actively controlled factor IX inhibitor using RNA aptamer technology for treatment of acute coronary syndromeAn update on recent patents on thrombin inhibitors (2010 - 2013)Nitrophorin 2, a factor IX(a)-directed anticoagulant, inhibits arterial thrombosis without impairing haemostasisTriggers, targets and treatments for thrombosis.Tissue factor and tissue factor pathway inhibitor as key regulators of global hemostasis: measurement of their levels in coagulation assays.Translation and Clinical Development of Antithrombotic Aptamers.Activated factor IX, factor XI and tissue factor identify patients with permanent atrial fibrillation treated with warfarin who are at risk of ischemic stroke.Rivaroxaban: a novel, oral, direct factor Xa inhibitor.Proteases as therapeutics.Tutorial in oral antithrombotic therapy: biology and dental implicationsInvestigational anticoagulants for hematological conditions: a new generation of therapies.Contemporary anticoagulation therapy in patients undergoing percutaneous intervention.A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor.The effect of surface contact activation and temperature on plasma coagulation with an RNA aptamer directed against factor IXa.Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study.The Intrinsic Pathway of Coagulation as a Target for Antithrombotic Therapy.New Anticoagulants for the Prevention and Treatment of Venous Thromboembolism.Coagulation Factor IX for Hemophilia B Therapy.A novel approach in potential anticoagulants from peptides epitope 558-565 of A2 subunit of factor VIII.Dose selection for a direct and selective factor IXa inhibitor and its complementary reversal agent: translating pharmacokinetic and pharmacodynamic properties of the REG1 system to clinical trial design.An Albumin-Oligonucleotide Assembly for Potential Combinatorial Drug Delivery and Half-Life Extension Applications.Comparison of reversal activity and mechanism of action of UHRA, andexanet, and PER977 on heparin and oral FXa inhibitors
P2860
Q27000201-F2EE48DA-3067-48D3-B6DD-9F6AFEF88E1FQ28299898-F854F0BB-A51A-4C3A-A448-5093851C660BQ33691654-CABE333A-DFC3-4DAF-8FD8-8C3E871A73A0Q33765444-FF30A6EB-6A1C-4485-B4A8-38154EAF7CE2Q34599765-2EBA28B7-CF77-4C5D-9EE8-C6297E8363DEQ36987361-7BD21F0B-5C6F-48EF-BBDC-A98B6811589CQ37243007-F3CF8A1E-B6E7-4FA6-B044-86945D54BF0FQ37377940-85D59005-CB15-4910-A546-093724456CF1Q37853216-96D0E840-6FE1-4CEC-858E-6DB6D3425F1AQ38092567-DA532A61-BDF5-4136-94F7-192672557626Q38123237-64039D05-E83C-4013-8E78-381E234CCE4BQ38186094-E8B50A47-A399-40B4-B309-EC1216C20367Q38293416-877F85E5-62A4-46D3-B5BC-888917B98B9EQ38320895-A9E9E9AB-E991-41DE-B8A4-C298B2C9DB1DQ38393247-D01F2217-2FF9-4CBA-B2D5-1B4B36F03933Q38956551-265BD3D2-27BD-4020-812B-BC2A029CBE8DQ39213540-C365D1A4-05AD-455F-B86A-D342BCBCC66AQ42256024-3C8ED890-8A50-476E-BAB4-FC8554506A92Q44608488-B01C8D96-1B2E-4DC0-9FCC-634D78D6A92BQ46642515-7C2B3E89-71BC-4D6B-914C-A205F26A438EQ47288556-F3ED6C85-A481-432F-9A40-2140794D6915Q58719429-4B33A44D-3CFC-44B7-8DAD-E1FC54399042
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Factor IXa inhibitors as novel anticoagulants.
@ast
Factor IXa inhibitors as novel anticoagulants.
@en
type
label
Factor IXa inhibitors as novel anticoagulants.
@ast
Factor IXa inhibitors as novel anticoagulants.
@en
prefLabel
Factor IXa inhibitors as novel anticoagulants.
@ast
Factor IXa inhibitors as novel anticoagulants.
@en
P2093
P1476
Factor IXa inhibitors as novel anticoagulants.
@en
P2093
Christopher P Rusconi
Emily L Howard
Kristian C D Becker
Richard C Becker
P304
P356
10.1161/01.ATV.0000259363.91070.F1
P407
P577
2007-02-01T00:00:00Z